)&F1y3x PHARMACEUTICAL APPENDIX to THE

Total Page:16

File Type:pdf, Size:1020Kb

)&F1y3x PHARMACEUTICAL APPENDIX to THE )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1 ALACEPRIL 74258-86-9 ACEFYLLINE PIPERAZINE 18428-63-2 ALAFOSFALIN 60668-24-8 ACEGLATONE 642-83-1 ALANINE 56-41-7 ACEGLUTAMIDE 2490-97-3 ALANOSINE 5854-93-3 ACEMANNAN 110042-95-0 ALAPROCLATE 60719-82-6 ACEMETACIN 53164-05-9 ALAZANINE TRICLOFENATE 5779-59-9 ACENEURAMIC ACID 131-48-6 ALBENDAZOLE 54965-21-8 ACENOCOUMAROL 152-72-7 ALBENDAZOLE OXIDE 54029-12-8 ACEPERONE 807-31-8 ALBIFYLLINE 107767-55-5 ACEPROMAZINE 61-00-7 ALBUTOIN 830-89-7 ACEPROMETAZINE 13461-01-3 ALCLOFENAC 22131-79-9 ACEQUINOLINE 42465-20-3 ALCLOMETASONE 67452-97-5 ACESULFAME 33665-90-6 ALCLOXA 1317-25-5 ACETAMINOSALOL 118-57-0 ALCURONIUM CHLORIDE 15180-03-7 ACETARSOL 97-44-9 ALDESULFONE SODIUM 144-75-2 ACETAZOLAMIDE 59-66-5 ALDIOXA 5579-81-7 ACETERGAMINE 3031-48-9 ALDOSTERONE 52-39-1 ACETIAMINE 299-89-8 ALENDRONIC ACID 66376-36-1 ACETIROMATE 2260-08-4 ALENTEMOL 112891-97-1 ACETOHEXAMIDE 968-81-0 ALEPRIDE 66564-15-6 ACETOHYDROXAMIC ACID 546-88-3 ALESTRAMUSTINE 139402-18-9 ACETOPHENAZINE 2751-68-0 ALEXIDINE 22573-93-9 ACETORPHINE 25333-77-1 ALEXITOL SODIUM 66813-51-2 ACETRYPTINE 3551-18-6 ALFACALCIDOL 41294-56-8 ACETYLCHOLINE CHLORIDE 60-31-1 ALFADEX 10016-20-3 ACETYLCYSTEINE 616-91-1 ALFADOLONE 14107-37-0 ACETYLDIGITOXIN 1111-39-3 ALFAPROSTOL 74176-31-1 ACETYLLEUCINE 99-15-0 ALFAXALONE 23930-19-0 ACETYLMETHADOL 509-74-0 ALFENTANIL 71195-58-9 ACEVALTRATE 25161-41-5 ALFETAMINE 4255-23-6 ACEXAMIC ACID 57-08-9 ALFUZOSIN 81403-80-7 ACICLOVIR 59277-89-3 ALGELDRATE 1330-44-5 ACIFRAN 72420-38-3 ALGESTONE 595-77-7 ACIPIMOX 51037-30-0 ALGLUCERASE 143003-46-7 ACITEMATE 101197-99-3 ALIBENDOL 26750-81-2 ACITRETIN 55079-83-9 ALICONAZOLE 63824-12-4 ACIVICIN 42228-92-2 ALIFEDRINE 78756-61-3 ACLANTATE 39633-62-0 ALIFLURANE 56689-41-9 ACLARUBICIN 57576-44-0 ALIMADOL 52742-40-2 ACLATONIUM NAPADISILATE 55077-30-0 ALIMEMAZINE 84-96-8 ACODAZOLE 79152-85-5 ALINIDINE 33178-86-8 ACONIAZIDE 13410-86-1 ALIPAMIDE 3184-59-6 ACOXATRINE 748-44-7 ALIZAPRIDE 59338-93-1 ACRIDOREX 47487-22-9 ALLETORPHINE 23758-80-7 ACRIFLAVINIUM CHLORIDE 8063-24-9 ALLOBARBITAL 52-43-7 ACRIHELLIN 67696-82-6 ALLOCLAMIDE 5486-77-1 ACRISORCIN 7527-91-5 ALLOCUPREIDE SODIUM 5965-40-2 ACRIVASTINE 87848-99-5 ALLOMETHADIONE 526-35-2 ACROCINONIDE 28971-58-6 ALLOPURINOL 315-30-0 ACRONINE 7008-42-6 ALLYLESTRENOL 432-60-0 ACTAGARDIN ALLYLPRODINE 25384-17-2 ACTAPLANIN 37305-75-2 ALLYLTHIOUREA 109-57-9 ACTARIT 18699-02-0 ALMADRATE SULFATE 60239-66-9 ACTINOQUINOL 15301-40-3 ALMAGATE 66827-12-1 ACTISOMIDE 96914-39-5 ALMASILATE 71205-22-6 ACTODIGIN 36983-69-4 ALMECILLIN 87-09-2 ADAFENOXATE 82168-26-1 ALMESTRONE 10448-96-1 ADAMEXINE 54785-02-3 ALMINOPROFEN 39718-89-3 )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 Table 1 (con.) Product CAS Number Product CAS Number ALMITRINE 27469-53-0 AMIKHELLINE 4439-67-2 ALMOKALANT 123955-10-2 AMILORIDE 2609-46-3 ALMOXATONE 84145-89-1 AMINDOCATE 31386-24-0 ALONACIC 105292-70-4 AMINEPTINE 57574-09-1 ALONIMID 2897-83-8 AMINITROZOLE 140-40-9 ALORACETAM 119610-26-3 AMINOACRIDINE 90-45-9 ALOSETRON 122852-42-0 AMINOCAPROIC ACID 60-32-2 ALOVUDINE 25526-93-6 AMINOETHYL NITRATE 646-02-6 ALOXIPRIN 9014-67-9 AMINOGLUTETHIMIDE 125-84-8 ALOXISTATIN 88321-09-9 AMINOMETRADINE 642-44-4 ALOZAFONE 65899-72-1 AMINOPHENAZONE 58-15-1 ALPERTINE 27076-46-6 AMINOPHENAZONE CYCLAMATE 747-30-8 ALPHACETYLMETHADOL 17199-58-5 AMINOPHYLLINE 317-34-0 ALPHAMEPRODINE 468-51-9 AMINOPROMAZINE 58-37-7 ALPHAMETHADOL 17199-54-1 AMINOPTERIN SODIUM 58602-66-7 ALPHAPRODINE 77-20-3 AMINOQUINOL 10023-54-8 ALPIDEM 82626-01-5 AMINOQUINURIDE 3811-56-1 ALPIROPRIDE 81982-32-3 AMINOREX 2207-50-3 ALPRAFENONE 124316-02-5 AMINOTHIAZOLE 96-50-4 ALPRAZOLAM 28981-97-7 AMINOXYTRIPHENE 5585-64-8 ALPRENOLOL 13655-52-2 AMIODARONE 1951-25-3 ALPROSTADIL 745-65-3 AMIPERONE 1580-71-8 ALRESTATIN 51411-04-2 AMIPHENAZOLE 490-55-1 ALSACTIDE 34765-96-3 AMIPIZONE 69635-63-8 ALTANSERIN 76330-71-7 AMIPRILOSE 56824-20-5 ALTAPIZONE 93277-96-4 AMIQUINSIN 13425-92-8 ALTECONAZOLE 93479-96-0 AMISOMETRADINE 550-28-7 ALTEPLASE 105857-23-6 AMISULPRIDE 71675-85-9 ALTIZIDE 5588-16-9 AMITEROL 54063-25-1 ALTOQUALINE 121029-11-6 AMITIVIR 111393-84-1 ALTRENOGEST 850-52-2 AMITRAZ 33089-61-1 ALTRETAMINE 645-05-6 AMITRIPTYLINE 50-48-6 ALTUMOMAB 156586-92-4 AMITRIPTYLINOXIDE 4317-14-0 ALUMINIUM CLOFIBRATE 24818-79-9 AMIXETRINE 24622-72-8 ALUSULF 61115-28-4 AMLEXANOX 68302-57-8 ALVERINE 150-59-4 AMLODIPINE 88150-42-9 ALVIRCEPT SUDOTOX 137487-62-8 AMOBARBITAL 57-43-2 AMADINONE 30781-27-2 AMOCARZINE 36590-19-9 AMAFOLONE 50588-47-1 AMODIAQUINE 86-42-0 AMANOZINE 537-17-7 AMOGASTRIN 16870-37-4 AMANTADINE 768-94-5 AMOLANONE 76-65-3 AMANTANIUM BROMIDE 58158-77-3 AMONAFIDE 69408-81-7 AMANTOCILLIN 10004-67-8 AMOPROXAN 22661-76-3 AMBAMUSTINE 85754-59-2 AMOPYROQUINE 550-81-2 AMBASILIDE 83991-25-7 AMOROLFINE 78613-35-1 AMBAZONE 539-21-9 AMOSCANATE 26328-53-0 AMBENONIUM CHLORIDE 115-79-7 AMOSULALOL 85320-68-9 AMBENOXAN 2455-84-7 AMOXAPINE 14028-44-5 AMBICROMIL 58805-38-2 AMOXECAINE 553-65-1 AMBOMYCIN 1402-81-9 AMOXICILLIN 26787-78-0 AMBROXOL 18683-91-5 AMOXYDRAMINE CAMSILATE 15350-99-9 AMBRUTICIN 58857-02-6 AMPEROZIDE 75558-90-6 AMBUCAINE 119-29-9 AMPHENIDONE 134-37-2 AMBUCETAMIDE 519-88-0 AMPHOTALIDE 1673-06-9 AMBUSIDE 3754-19-6 AMPHOTERICIN B 1397-89-3 AMCINAFAL 3924-70-7 AMPICILLIN 69-53-4 AMCINAFIDE 7332-27-6 AMPIROXICAM 99464-64-9 AMCINONIDE 51022-69-6 AMPROLIUM 121-25-5 AMEBUCORT 83625-35-8 AMPYRIMINE 5587-93-9 AMEDALIN 22136-26-1 AMPYZINE 5214-29-9 AMELTOLIDE 787-93-9 AMQUINATE 17230-85-2 AMESERGIDE 121588-75-8 AMRINONE 60719-84-8 AMETANTRONE 64862-96-0 AMRUBICIN 110267-81-7 AMEZEPINE 60575-32-8 AMSACRINE 51264-14-3 AMEZINIUM METILSULFATE 30578-37-1 AMTOLMETIN GUACIL 87344-06-7 AMFEBUTAMONE 34911-55-2 AMYLMETACRESOL 1300-94-3 AMFECLORAL 5581-35-1 ANAGESTONE 2740-52-5 AMFENAC 51579-82-9 ANAGRELIDE 68475-42-3 AMFEPENTOREX 15686-27-8 ANARITIDE 95896-08-5 AMFEPRAMONE 90-84-6 ANAXIRONE 77658-97-0 AMFETAMINE 300-62-9 ANAZOCINE 15378-99-1 AMFETAMINIL 17590-01-1 ANAZOLENE SODIUM 3861-73-2 AMFLUTIZOLE 82114-19-0 ANCAROLOL 75748-50-4 AMFOMYCIN 1402-82-0 ANCITABINE 31698-14-3 AMFONELIC ACID 15180-02-6 ANCROD 9046-56-4 AMICARBALIDE 3459-96-9 ANDOLAST 132640-22-3 AMICIBONE 23271-63-8 ANDROSTANOLONE 521-18-6 AMICYCLINE 5874-95-3 ANGIOTENSINAMIDE 53-73-6 AMIDANTEL 49745-00-8 ANGIOTENSIN II 4474-91-3 AMIDAPSONE 3569-77-5 ANIDOXIME 34297-34-2 AMIDEFRINE MESILATE 1421-68-7 ANILAMATE 5591-49-1 AMIFLAMINE 77518-07-1 ANILERIDINE 144-14-9 AMIFLOVERINE 54063-24-0 ANILOPAM 53716-46-4 AMIFLOXACIN 86393-37-5 ANIPAMIL 83200-10-6 AMIFOSTINE 20537-88-6 ANIRACETAM 72432-10-1 AMIKACIN 37517-28-5 ANIROLAC 66635-85-6 )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 5 Table 1 (con.) ProductCAS Number Product CAS Number ANISACRIL 5129-14-6 AVIZAFONE 65617-86-9 ANISINDIONE 117-37-3 AVOBENZONE 70356-09-1 ANISOPIROL 442-03-5 AVOPARCIN 37332-99-3 ANISTREPLASE 81669-57-0 AVRIDINE 35607-20-6 ANITRAZAFEN 63119-27-7 AXAMOZIDE 85076-06-8 ANPIRTOLINE 98330-05-3 AZABON 1150-20-5 ANSOXETINE 79130-64-6 AZABUPERONE 2856-81-7 ANTAFENITE 15301-45-8 AZACITIDINE 320-67-2 ANTAZOLINE 91-75-8 AZACLORZINE 49864-70-2 ANTAZONITE 25422-75-7 AZACONAZOLE 60207-31-0 ANTELMYCIN 1402-84-2 AZACOSTEROL 313-05-3 ANTHIOLIMINE 305-97-5 AZACYCLONOL 115-46-8 ANTIENITE 5029-05-0 AZAFTOZINE 54063-26-2 ANTRAFENINE 55300-29-3 AZALOMYCIN 54182-65-9 ANTRAMYCIN 4803-27-4 AZALOXAN 72822-56-1 APAFANT 105219-56-5 AZAMETHONIUM BROMIDE 306-53-6 APALCILLIN 63469-19-2 AZAMULIN 76530-44-4 APICYCLINE 15599-51-6 AZANATOR 37855-92-8 APOVINCAMINE 4880-92-6 AZANIDAZOLE 62973-76-6 APRACLONIDINE 66711-21-5 AZAPERONE 1649-18-9 APRAMYCIN 37321-09-8 AZAPROCIN 448-34-0 APRIKALIM 92569-65-8 AZAPROPAZONE 13539-59-8 APRINDINE 37640-71-4 AZAQUINZOLE 5234-86-6 APROBARBITAL 77-02-1 AZARIBINE 2169-64-4 APROFENE 3563-01-7 AZASERINE 115-02-6 APROSULATE SODIUM 123072-45-7 AZASETRON 123040-69-7 APROTININ 9004-04-0 AZASPIRIUM CHLORIDE 34959-30-3 APTAZAPINE 71576-40-4 AZASTENE 13074-00-5 APTOCAINE 19281-29-9 AZATADINE 3964-81-6 ARANIDIPINE 86780-90-7 AZATEPA 125-45-1 ARANOTIN 19885-51-9 AZATHIOPRINE 446-86-6 ARAPROFEN 15250-13-2 AZELAIC ACID 123-99-9
Recommended publications
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
    [Show full text]
  • TARIF DES DOUANES - ANNEXE 99 - I
    TARIF DES DOUANES - ANNEXE 99 - i Chapitre 99 DISPOSITIONS DE CLASSIFICATION SPÉCIALE - COMMERCIALES Notes. 1. Les dispositions du présent Chapitre ne sont pas régies par la règle de spécificité de la Règle générale interprétative 3 a). 2. Les marchandises qui peuvent être classées dans les dispositions du Chapitre 99, sont classées dans le Chapitre 98 si elles peuvent également être classées dans ce chapitre. 3. Les marchandises peuvent être classées dans un numéro tarifaire du présent Chapitre et peuvent bénéficier des taux de droits de douane du tarif de la nation la plus favorisée ou du tarif de préférence prévus au présent Chapitre qui s’appliquent à ces marchandises selon le traitement tarifaire applicable selon le pays d’origine, mais ce classement est subordonné au classement préalable de celles-ci dans un numéro tarifaire des Chapitres 1 à 97 et à l’observation des conditions prévues par les textes d’application qui leurs sont applicables. 4. Les termes utilisés dans ce Chapitre et dans les Chapitres 1 à 97 s’entendent au sens de ces derniers Chapitres. Émis 1 janvier 2018 99 - 1 TARIF DES DOUANES - ANNEXE Numéro Unité Tarif de la Tarif de préférence SS Dénomination des marchandises tarifaire de mes. N.P.F. applicable 9901.00.00 Articles et matières devant servir à la fabrication ou à la réparation des En fr. TPAC, TPMD, TPG, produits suivants devant être utilisés dans la pêche commerciale ou TÉU, TM, TMÉU, TACI, dans la récolte commerciale de plantes aquatiques : TC, TCR, TI, TN, TSL, TP, TCOL, TJ, TPA, Appâts artificiels; TNH, TKR, TCUE, TUA : En fr.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: wolfgang.froestl@acimmune.com GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Neurobiological and Neurobehavioral Mechanisms of Chronic Alcohol Drinking
    Neurobiological and Neurobehavioral Mechanisms of Chronic Alcohol Drinking Neurobiological and Neurobehavioral Mechanisms of Chronic Alcohol Drinking Alcoholism comprises a set of complex behaviors seeking behaviors, have been developed. These in which an individual becomes increasingly models, which remain an integral part of the preoccupied with obtaining alcohol. These study of alcoholism, include animals that pref- behaviors ultimately lead to a loss of control over erentially drink solutions containing alcohol, consumption of the drug and to the development animals that self-administer alcohol during of tolerance, dependence, and impaired social and withdrawal, animals with a history of dependence occupational functioning. that self-administer alcohol, and animals that self- administer alcohol after a period of abstinence Although valuable information regarding toler- from the drug. Genetic models for alcoholism ance and dependence has been, and continues to also exist and include animals that have been bred be, gathered through human studies, much of the selectively for high alcohol consumption. Studies detailed understanding of the impact of exposure using such models are uncovering the systemic, to alcohol on behavior and on the biological cellular, and molecular neurobiological mech- mechanisms underlying those behaviors has been anisms that appear to contribute to chronic obtained through the use of animal models for alcohol consumption. The challenge of current alcoholism and a variety of in vitro, or cellular, and future studies is to understand which specific systems. Through the use of cellular systems and cellular and subcellular systems undergo mole- animal models, researchers can control the genetic cular changes to influence tolerance and depen- background and experimental conditions under dence in motivational systems that lead to which a specific alcohol-related behavior or chronic drinking.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Designing Inhibitors Via Molecular Modelling Methods for Monoamine Oxidase Isozymes a and B Filiz Varnali Kadir Has Universit
    DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI M.S. in Computational Biology and Bioinformatics, Kadir Has University, 2012 Submitted to the Graduate School of Science and Engineering in partial fulfilment of the requirements for the degree of Master of Science in Computational Biology and Bioinformatics KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B Abstract In drug development studies, a large number of new drug candidates (leads) have to be synthesized and optimized by changing several moieties of the leads in order to increase efficacies and decrease toxicities. Each synthesis of these new drug candidates include multi-steps procedures. Overall, discovering a new drug is a very time-consuming and very costly works. The development of molecular modelling programs and their applications in pharmaceutical research have been formalized as a field of study known computer assisted drug design (CADD) or computer assisted molecular design (CAMD). In this study, using the above techniques, Monoamine Oxidase isozymes, which play an essential role in the oxidative deamination of the biogenic amines, were studied. Compounds that inhibit these isozymes were shown to have therapeutic value in a variety of conditions including several psychiatric and neurological as well as neurodegenerative diseases. First, a series of new pyrazoline derivatives were screened using molecular modelling and docking methods and promising lead compounds were selected, and proposed for synthesis as novel selective MAO-A or –B inhibitors.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
    1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]